Steris (STE) official guidance

Reflecting the recently announced investment to build a formulated chemistries manufacturing Center of Excellence in North Carolina, capital expenditures are now anticipated to be approximately $450 million compared with prior expectations of $375 million.

Adjusted earnings per diluted share are anticipated to be in the range of $11.10 to $11.30, unchanged from prior expectations.

| Net income from continuing operations per diluted share | $8.92 - $9.12 |

| Free Cash Flow | $800.0 |

| Cash flows from operating activities | $1,250.0 |

This includes as reported revenue growth of 7-8% and constant currency organic revenue growth of 6-7%.

The Company currently expects to incur total pre-tax restructuring charges of approximately $55 million to $70 million, consisting of approximately $40 million to $50 million of cash expenditures and approximately $15 million to $20 million of non-cash charges.

The Company currently expects to incur total pre-tax restructuring charges of approximately $55 million to $70 million, consisting of approximately $40 million to $50 million of cash expenditures and approximately $15 million to $20 million of non-cash charges.

The Company currently expects to incur total pre-tax restructuring charges of approximately $55 million to $70 million, consisting of approximately $40 million to $50 million of cash expenditures and approximately $15 million to $20 million of non-cash charges.

This includes as reported revenue growth of 7-8% and constant currency organic revenue growth of 6-7%.

In terms of other opportunities, challenges, the bonus tailwind is about $20 million.

In fiscal 2027, we will build a new sterility assurance manufacturing plant in Mentor, Ohio, which will ultimately allow us to consolidate existing U.S. production into one new state-of-the-art manufacturing center of excellence to serve our healthcare and life science customers. We will invest about $60 million over two years and expect that plant to be operational by the end of calendar 2027.

This is reflected in our estimate of 25% in fiscal 2027.

We will also use about $50 million for additional incentive compensation payments due in June and the remainder of our EO settlement payments over the year.

Underlying our free cash flow expectations, we expect that net working capital will grow in line with volumes.

For fiscal 2027, EBIT margins are anticipated to expand approximately 50 basis points at the high end of our outlook.

U.S. procedure volume continues to grow mid-single digits, a level we expect to be consistent in fiscal 2027.

These two acquisitions are expected to contribute combined revenues of approximately $45 million to fiscal 2027.

Going forward, we expect to utilize excess cash to consistently buy back shares in the range of $200 million-$300 million per year.

our incremental tariffs in 2026 was $46 million, which puts us at a total tariff spend between $60 million and $65 million, and that's what we're modeling for 2027.